Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 to Develop microRNA-Based Colorectal Cancer Diagnostic for IntegraGen

Premium

British diagnostics service firmLab21 said this week that it has signed a deal to collaborate with diagnostics developer IntegraGen to develop a microRNA-based assay for colorectal cancer.

According to Lab21, it will use its proprietary PCR technology to develop an assay that can detect hsa-miR-31-3p, which is believed to predict response to EGFR inhibitor therapy, such as Erbitux, in KRAS wild-type patients with metastatic colorectal cancer.

The approximately 40 percent of colorectal cancer patients who carry the mutation are not good candidates for EGFR inhibitors.

Specific terms of the arrangement were not disclosed.

IntegraGen CEO Bernard Courtieu said in a statement that the assay could be ready for commercialization in Europe by early 2014.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.